Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help?
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Study Design, Inclusion and Exclusion Criteria, and Definitions
4.2. Population Analysis
4.3. Statistical Analysis
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Verweij, P.E.; Brüggemann, R.J.M.; Wauters, J.; Rijnders, B.J.A.; Chiller, T.; van de Veerdonk, F.L. Influenza coinfection: Be(a)ware of invasive aspergillosis. Clin. Infect. Dis. 2020, 70, 349–350. [Google Scholar] [CrossRef] [PubMed]
- Meersseman, W.; Vandecasteele, S.J.; Wilmer, A.; Verbeken, E.; Peetermans, W.E.; Van Wijngaerden, E. Invasive aspergillosis in critically ill patients without malignancy. Am. J. Respir. Crit. Care Med. 2004, 170, 621–625. [Google Scholar] [CrossRef] [PubMed]
- Cornillet, A.; Camus, C.; Nimubona, S.; Gandemer, V.; Tattevin, P.; Belleguic, C.; Chevrier, S.; Meunier, C.; Lebert, C.; Aupée, M.; et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: A 6-year survey. Clin. Infect. Dis. 2006, 43, 577–584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Safavian, S.R.; Landgrebe, D. A survey of decision tree classifier methodology. IEEE Trans. Syst. Man Cybern. 1991, 21, 660–674. [Google Scholar] [CrossRef] [Green Version]
- Kononenko, I. Machine learning for medical diagnosis: History, state of the art and perspective. Artif. Intell. Med. 2001, 23, 89–109. [Google Scholar] [CrossRef]
- Chai, L.Y.; van de Veerdonk, F.; Marijnissen, R.J.; Cheng, S.C.; Khoo, A.L.; Hectors, M.; Lagrou, K.; Vonk, A.G.; Maertens, J.; Joosten, L.A.; et al. Anti-Aspergillus human host defence relies on type 1 T helper (Th1), rather than type 17 T helper (Th17), cellular immunity. Immunology 2010, 130, 46–54. [Google Scholar] [CrossRef] [PubMed]
- Hartemink, K.J.; Paul, M.A.; Spijkstra, J.J.; Girbes, A.R.; Polderman, K.H. Immunoparalysis as a cause for invasive aspergillosis? Intensive Care Med. 2003, 29, 2068–2071. [Google Scholar] [CrossRef] [PubMed]
- Bellelli, V.; d’Ettorre, G.; Celani, L.; Borrazzo, C.; Ceccarelli, G.; Venditti, M. Clinical significance of lymphocytopenia in patients hospitalized with pneumonia caused by influenza virus. Crit. Care 2019, 23, 330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Crum-Cianflone, N.F. Invasive Aspergillosis Associated with Severe Influenza Infections. In Open Forum Infectious Diseases; Oxford University Press: Oxford, UK, 2016; Volume 3. [Google Scholar] [CrossRef] [Green Version]
- Huang, L.; Zhang, N.; Huang, X.; Xiong, S.; Feng, Y.; Zhang, Y.; Li, M.; Zhan, Q. Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective study and review of the literature. Clin. Respir. J. 2019, 13, 202–211. [Google Scholar] [CrossRef] [PubMed]
- Lionakis, M.S.; Kontoyiannis, D.P. Glucocorticoids and invasive fungal infections. Lancet 2003, 362, 1828–1838. [Google Scholar] [CrossRef]
- Ng, T.T.; Robson, G.D.; Denning, D.W. Hydrocortisone-enhanced growth of Aspergillus spp.: Implications for pathogenesis. Microbiology 1994, 140 Pt 9, 2475–2479. [Google Scholar] [CrossRef] [Green Version]
- De Pauw, B.; Walsh, T.J.; Donnelly, J.P.; Stevens, D.A.; Edwards, J.E.; Calandra, T.; Pappas, P.G.; Maertens, J.; Lortholary, O.; Kauffman, C.A.; et al. European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses StudyGroup (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46, 1813–1821. [Google Scholar] [CrossRef] [PubMed]
- Schauwvlieghe, A.F.A.D.; Rijnders, B.J.A.; Philips, N.; Verwijs, R.; Vanderbeke, L.; Van Tienen, C.; Lagrou, K.; Verweij, P.E.; Van de Veerdonk, F.L.; Gommers, D.; et al. Dutch-Belgian Mycosis study group. Invasive aspergillosis in patients admitted to the Intensive care unit with severe influenza: A retrospective cohort study. Lancet Respir. Med. 2018, 6, 782–792. [Google Scholar] [CrossRef]
Population Characteristics: Continuous Variables | |||
Total (77 pt) | Median | IQR 25% | IQR 75% |
Age (years) | 56.5 | 26.8 | 74.5 |
Weight (kg) | 68 | 55 | 75 |
† WBC (cell/µL) | 8640 | 5250 | 10,770 |
Neutrophils (cell/µL) | 5730 | 2990 | 9190 |
Neutrophils % | 78 | 6 | 88 |
Lymphocytes (cell/µL) | 810 | 560 | 1400 |
Lymphocytes % | 11 | 6 | 29 |
‡ CRP µg/L | 39,150 | 10,250 | 67,850 |
CHARLSON | 2 | 0 | 5 |
SOFA score | 1 | 0 | 3 |
Methylprednisolone mg/kg/day | 0.6 | 0.5 | 1 |
§ LOS (days) | 12 | 7 | 34 |
Population Characteristics: Categorical Variables | |||
Patients | Patients (%) | ||
Male | 39 | 50.6 | |
Female | 38 | 49.4 | |
Caucasian | 70 | 90.9 | |
Asian | 5 | 6.5 | |
African | 2 | 2.6 | |
Smoker | 35 | 45.5 | |
Alcohol | 4 | 5.2 | |
No comorbidities | 17 | 22.1 | |
† Ischemic/CHF | 21 | 27.3 | |
‡ COPD | 14 | 18.2 | |
§ CKD | 6 | 7.8 | |
Cirrhosis | 2 | 2.6 | |
Diabetes type 2 | 15 | 19.5 | |
Neurologic diseases | 20 | 26 | |
Malignancies | 6 | 7.8 | |
Autoimmune disorders | 5 | 6.5 | |
Psychiatric diseases | 8 | 10.4 | |
Pregnancy | 2 | 2.6 | |
Influenza A | 48 | 62.3 | |
Influenza H1N1 | 29 | 37.7 | |
Community-acquired | 67 | 87 | |
Hospital-acquired | 10 | 13 | |
Nasal swab | 73 | 94.8 | |
Pharyngeal swab | 3 | 3.9 | |
Nasopharyngeal aspirate | 1 | 1.3 | |
Pneumonia (chest X-ray) | 46 | 59.7 | |
Pleural effusion | 17 | 22.1 | |
No oxygen supplementation | 34 | 44.1 | |
Oxygen supplementation | 24 | 31.2 | |
¶ NIV | 6 | 7.8 | |
£ IMV | 13 | 16.9 | |
$ ECMO | 2 | 2.6 | |
Hemodialysis | 4 | 5.2 | |
% ICU/emergency | 17 | 22.1 | |
& BSI | 12 | 15.6 | |
Lung superinfection | 7 | 9.1 | |
Fungal superinfection | 6 | 7.8 | |
IPA | 5 | 6.5 | |
Oseltamivir | 66 | 85.7 | |
Antifungal | 19 | 24.7 | |
Antibiotic | 59 | 76.6 | |
Corticosteroid | 34 | 44.1 | |
Death | 11 | 14.3 |
Risk Factors | Influenza and IPA | Influenza | p-Value |
---|---|---|---|
(n = 5) | (n = 72) | ||
Age (years) | 59 (58–71) | 53 (26.5–75) | 0.723 |
Male | 3 (60) | 36 (50) | 0.667 |
Weight (kg) | 80 (70–80) | 65.7 (54.3–75) | 0.740 |
Caucasian | 4 (80) | 66 (92) | 0.381 |
Smoker | 5 (100) | 30 (42) | 0.0124 |
Alcohol abuse | 0 | 4 (5) | 0.603 |
Pregnancy | 0 | 2 (3) | 0.706 |
† Ischemic/CHF | 2 (40) | 19 (25) | 0.451 |
‡ COPD | 4 (80) | 10 (13) | <0.001 |
CKD | 1 (20) | 5 (7) | 0.267 |
Cirrhosis | 0 | 2 (3) | 0.717 |
Diabetes type 2 | 0 | 15 (21) | 0.259 |
Neurologic diseases | 1 (20) | 19 (26) | 0.911 |
Malignancies | 0 | 6 (8) | 0.505 |
Autoimmune disorders | 1 (20) | 4 (6) | 0.210 |
Psychiatric diseases | 1 (20) | 7 (9) | 0.431 |
Charlson comorbidity index | 2 (1–6) | 2 (0–5) | 0.889 |
Risk Factors | Influenza and IPA | Influenza | p-Value |
---|---|---|---|
(n = 5) | (n = 72) | ||
Influenza A | 2 (40) | 46 (64) | 0.287 |
Influenza H1N1 | 3 (60) | 26 (36) | 0.287 |
Community acquired | 4 (80) | 63 (87) | 0.443 |
Hospital acquired | 1 (20) | 9 (13) | 0.532 |
† WBC (cell/mmc) | 9820 (8640–10,000) | 8315 (5147.5–10,785) | 0.529 |
Neutrophils (cell/µL) | 9181 (7640.0–9400) | 5550 (2920–9175) | 0.328 |
Lymphocytes (cell/µL) | 300 (274–304) | 875 (587.5–1467.5) | <0.001 |
‡ CRP µg/L | 53,650 (49,325–61,000) | 35,650 (10,150–69,550) | 0.332 |
§ SOFA score | 5 (3–13) | 1 (0–2) | 0.095 |
Pneumonia chest X ray | 5 (100) | 41 (53) | 0.042 |
Severe flue | 5 (100) | 38 (49) | 0.029 |
Corticosteroid | 5 (100) | 29 (40) | 0.009 |
Methylprednisolone mg/kg/day | 1 (1–1.1) | 0.6 (0.5–0.7) | <0.001 |
Clinical Variables | Influenza and IPA (n = 5) | Influenza (n = 72) | p-Value |
---|---|---|---|
† BSI | 3 (60) | 9 (13) | 0.006 |
Bacterial lung superinfection | 1 (20) | 6 (83) | <0.001 |
Pneumocystosis | 0 | 1 (1) | 0.792 |
‡ IMV | 5 (100) | 8 (11) | <0.001 |
ECMO | 1 (20) | 1 (1) | 0.012 |
Hemodialysis | 2 (40) | 2 (3) | 0.003 |
LOS (days) | 37 (33–49) | 11 (7–30) | 0.159 |
Death | 5 (100) | 6 (8) | <0.001 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bellelli, V.; Siccardi, G.; Conte, L.; Celani, L.; Congeduti, E.; Borrazzo, C.; Santinelli, L.; Innocenti, G.P.; Pinacchio, C.; Ceccarelli, G.; et al. Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help? Antibiotics 2020, 9, 644. https://doi.org/10.3390/antibiotics9100644
Bellelli V, Siccardi G, Conte L, Celani L, Congeduti E, Borrazzo C, Santinelli L, Innocenti GP, Pinacchio C, Ceccarelli G, et al. Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help? Antibiotics. 2020; 9(10):644. https://doi.org/10.3390/antibiotics9100644
Chicago/Turabian StyleBellelli, Valeria, Guido Siccardi, Livia Conte, Luigi Celani, Elena Congeduti, Cristian Borrazzo, Letizia Santinelli, Giuseppe Pietro Innocenti, Claudia Pinacchio, Giancarlo Ceccarelli, and et al. 2020. "Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help?" Antibiotics 9, no. 10: 644. https://doi.org/10.3390/antibiotics9100644
APA StyleBellelli, V., Siccardi, G., Conte, L., Celani, L., Congeduti, E., Borrazzo, C., Santinelli, L., Innocenti, G. P., Pinacchio, C., Ceccarelli, G., Venditti, M., & d’Ettorre, G. (2020). Preliminary Attempt to Predict Risk of Invasive Pulmonary Aspergillosis in Patients with Influenza: Decision Trees May Help? Antibiotics, 9(10), 644. https://doi.org/10.3390/antibiotics9100644